US pharma giant Regeneron acquires bankrupt DNA testing startup 23andMe
American pharmaceutical company Regeneron Pharmaceuticals announced that it is acquiring almost all of the assets of DNA research startup 23andMe for $256 million. This was reported by the company's press service.
The deal is subject to U.S. bankruptcy court and regulatory approvals, and the acquisition is expected to close in the third quarter of 2025.
23andMe will operate as a direct or indirect subsidiary of Regeneron Pharmaceuticals and will continue to engage in genetic research.
Regeneron also plans to retain the staff that worked on the startup and will adhere to all privacy policies related to the processing of customer personal data.
An independent, court-appointed Ombudsman for the protection of personal data of customers will be involved to monitor compliance with the standards.
The deal includes the acquisition of:
- Personal Genome Service;
- Total Health service;
- Research Services research division;
- biobank of the company 23andMe.
At the same time, the company will not acquire the online medical consultation service Lemonaid Health – it will remain a separate asset.
- On March 24, it became known that the biotechnology company 23andMe had lost more than 99% of its capitalization and filed for bankruptcy.
